As far as the Directors are aware, immediately following the completion of the [**REDACTED**] (assuming that the [**REDACTED**] and the [**REDACTED**] are not exercised and all Preferred Shares have been converted into Ordinary Shares on a one-to-one basis), the following persons will have an interest and/or short position in the Shares or underlying Shares which will be required to be disclosed to the Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of the Company:

		As of the Latest Practicable Date		Immediately following the completion of the [REDACTED](1)	
Name of Shareholder	**Nature of interest**	**Number of the Shares**	**Shareholding**	**Number of the Shares**	**Shareholding**
			%		%
Dr. Wang Zaiqi	Beneficial owner	18,569,956	15.16	[**REDACTED**]	[**REDACTED**]
	Interest jointly held with another person(2)	13,900,000	11.35	[**REDACTED**]	[**REDACTED**]
NanGene One Limited	Beneficial owner	5,900,000	4.82	[**REDACTED**]	[**REDACTED**]
	Interest jointly held with another person(2)	26,569,956	21.69	[**REDACTED**]	[**REDACTED**]
Mr. Cao Fei	Interest in controlled corporation(3)	5,900,000	4.82	[**REDACTED**]	[**REDACTED**]
	Interest jointly held with another person(2)	26,569,956	21.69	[**REDACTED**]	[**REDACTED**]
Synomed One Limited	Beneficial owner	4,650,000	3.80	[**REDACTED**]	[**REDACTED**]
	Interest jointly held with another person(2)	27,819,956	22.71	[**REDACTED**]	[**REDACTED**]
Dr. Zhang Ning	Interest in controlled corporation(4)	4,650,000	3.80	[**REDACTED**]	[**REDACTED**]
	Interest jointly held with another person(2)	27,819,956	22.71	[**REDACTED**]	[**REDACTED**]
Dr. Yang Weiping	Beneficial owner	3,350,000	2.73	[**REDACTED**]	[**REDACTED**]
	Interest jointly held with another person(2)	29,119,956	23.77	[**REDACTED**]	[**REDACTED**]
NanGene Two Limited	Beneficial owner(5)	9,208,946	7.52	[**REDACTED**]	[**REDACTED**]
Futu Trustee Limited	Trustee(5)	9,208,946	7.52	[**REDACTED**]	[**REDACTED**]
Future Industry Investment Fund II	Beneficial owner	12,875,000	10.51	[**REDACTED**]	[**REDACTED**]
CS Capital Co., Ltd.	Interest in controlled corporation(6)	12,875,000	10.51	[**REDACTED**]	[**REDACTED**]
Shenzhen Pengfu Biopharmaceutical Industry Private Equity Investment Partnership Enterprise (Limited Liability Partnership) (深圳市鵬復生物醫藥產業私募股權投資基金合夥企業(有限合夥)) ("**FHC**")	Beneficial owner	10,985,398	8.97	[**REDACTED**]	[**REDACTED**]

Name of Shareholder	Nature of interest	As of the Latest Practicable Date		Immediately following the completion of the [REDACTED][1]	
		Number of the Shares	Shareholding	Number of the Shares	Shareholding
			%		%
Shenzhen Guiding Fund Investment Co., Ltd. (深圳市引導基金投資有限公司).	Interest in controlled corporation[7]	10,985,398	8.97	[REDACTED]	[REDACTED]
Shenzhen Fuxin Shenyao Investment Partnership (Limited Partnership) (深圳複鑫深耀投資合夥企業(有限合夥)) ("**Shenzhen Fuxin**").	Interest in controlled corporation[7]	10,985,398	8.97	[REDACTED]	[REDACTED]
Shanghai Fosun Pingyao Investment Management Co., Ltd. (上海複星平耀投資管理有限公司) ("**Fosun Pingyao**")	Interest in controlled corporation[7]	10,985,398	8.97	[REDACTED]	[REDACTED]
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海複星醫藥(集團)股份有限公司) ("**Fosun Pharmaceutical**") .	Interest in controlled corporation[7]	10,985,398	8.97	[REDACTED]	[REDACTED]
I-Bridge Healthcare Fund, L.P. ("**I-Bridge**").	Beneficial owner	10,611,406	8.66	[REDACTED]	[REDACTED]
I-Bridge Healthcare Fund GP, L.P.	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
I-Bridge Capital GP, Ltd.	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
C-Bridge SLP, L.P. . .	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
C-Bridge Capital GP, Ltd.	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
TF Capital, Ltd	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
TF Capital II, Ltd . . .	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
Kang Hua Investment Company Limited .	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]
Ms. Dan Yang	Interest in controlled corporation[8]	10,611,406	8.66	[REDACTED]	[REDACTED]

Name of Shareholder	Nature of interest	As of the Latest Practicable Date		Immediately following the completion of the [REDACTED](1)	
		Number of the Shares	Shareholding	Number of the Shares	Shareholding
			%		%
Nova Aqua Limited	Interest in controlled corporation(8)	12,086,406	9.87	[REDACTED]	[REDACTED]
Mr. Fu Wei	Beneficiary of a trust Founder of a trust(8)	12,086,406	9.87	[REDACTED]	[REDACTED]
AIHC Master Fund	Beneficial owner	9,726,094	7.94	[REDACTED]	[REDACTED]
AIH Capital Group Limited	Interest in controlled corporation(9)	9,726,094	7.94	[REDACTED]	[REDACTED]
Mr. Zhang Wei	Beneficial owner	429,166	0.35	[REDACTED]	[REDACTED]
	Interest in controlled corporation(9)	9,726,094	7.94	[REDACTED]	[REDACTED]

(1) The calculation is based on the assumption that (i) the [**REDACTED**] and the [**REDACTED**] are not exercised, and (ii) all Preferred Shares have been converted into Shares on a one-to-one basis immediately upon the completion of the [**REDACTED**].

(2) Pursuant to the Acting-in-Concert Agreement, the Concert Parties (namely, Dr. Wang Zaiqi, Mr. Cao Fei, Dr. Zhang Ning and Dr. Yang Weiping) have agreed to act in concert in managing our Group in the following manners: (i) by reaching consensus on proposals related to the Company's operation and development and voting on such resolutions at the Company's general meetings; and (ii) in the event that no consensus is reached among the Concert Parties, they will vote in concurrence with Dr. Wang Zaiqi on such proposals. The Acting-in-Concert Agreement is originally effective for five years from July 24, 2020 and has been renewed for an additional five years pursuant to a supplemental agreement dated July 24, 2025. As a result, each of Dr. Wang Zaiqi, NanGene One Limited (the special purpose vehicle of Mr. Cao Fei), Mr. Cao Fei, Synomed One Limited (the special purpose vehicle of Dr. Zhang Ning), Dr. Zhang Ning and Dr. Yang Weiping is deemed to be interested in all the Shares in which each of them is interested under the SFO.

(3) As of the Latest Practicable Date, NanGene One Limited was wholly owned by Mr. Cao Fei. As a result, Mr. Cao Fei is deemed to be interested in the 5,900,000 Shares held by NanGene One Limited under the SFO.

(4) As of the Latest Practicable Date, Synomed One Limited was wholly owned by Dr. Zhang Ning. As a result, Dr. Zhang Ning is deemed to be interested in the 4,650,000 Shares held by Synomed One Limited under the SFO.

(5) NanGene Two Limited is a platform holding the underlying incentive Shares under the Pre-[**REDACTED**] Equity Incentive Plan. As at the Latest Practicable Date, NanGene Two Limited is wholly-owned by Futu Trustee Limited as trustee of InxMed Share Incentive Trust, which was established by the Company as the settlor for the purpose of the Pre-[**REDACTED**] Equity Incentive Plan. As such, Futu Trustee Limited is deemed to be interested in the 9,208,946 Shares held by NanGene Two Limited. See "Appendix IV — Statutory and General Information — Pre-[**REDACTED**] Equity Incentive Plan" in this document for further details.

(6) As of the Latest Practicable Date, Future Industry Investment Fund II was managed by its general partner CS Capital Co., Ltd., which also holds part of the partnership interests. As a result, CS Capital Co., Ltd. is deemed to be indirectly interested in part of the 12,875,000 Shares held by Future Industry Investment Fund II under the SFO.

(7) As of the Latest Practicable Date, FHC was managed by its general partner Shenzhen Fuxin and owned as to 50% by its largest limited partner, Shenzhen Guiding Fund Investment Co., Ltd. The general partner of Shenzhen Fuxin is Fosun Pingyao, which is in turn wholly owned by Fosun Pharmaceutical, a company listed on the Shanghai Stock Exchange (stock code: 600196) and the Hong Kong Stock Exchange (stock code: 2196). Shenzhen Guiding Fund Investment Co., Ltd. is wholly owned by Shenzhen Municipal Finance Bureau.

As a result, each of Shenzhen Fuxin, Shenzhen Guiding Fund Investment Co., Ltd., Fosun Pingyao and Fosun Pharmaceutical is deemed to be interested in the 10,985,398 Shares held by FHC under the SFO.

(8) As of the Latest Practicable Date, I-Bridge was managed by its general partner I-Bridge Healthcare Fund GP, L.P., whose general partner is I-Bridge Capital GP, Ltd. I-Bridge Capital GP, Ltd. was held as to 70% by C-Bridge SLP, L.P. C-Bridge SLP, L.P. was owned as to 50% by its limited partner, Mr. Fu Wei, and managed by its general partner C-Bridge Capital GP, Ltd., which is owned as to 45% and 38.34% by TF Capital, Ltd and TF Capital II, Ltd, respectively. Kang Hua Investment Company Limited has controlling interest in TF Capital, Ltd, and Kang Hua Investment Company Limited is wholly owned by Ms. Dan Yang. TF Capital II, Ltd is owned as to 47.83% by Nova Aqua Limited. The entire interest in Nova Aqua Limited is held through a trust which was established by Mr. Wei Fu (as the settlor) for the benefit of Mr. Wei Fu and his family.

As of the Latest Practicable Date, JVC Project I Limited was wholly owned by C-Bridge Joint Value Creation Limited, which is wholly owned by Nova Aqua Limited.

As a result, (i) each of I-Bridge Healthcare Fund GP, L.P., I-Bridge Capital GP, Ltd., C-Bridge SLP, L.P., C-Bridge Capital GP, Ltd., TF Capital, Ltd, TF Capital II, Ltd, Kang Hua Investment Company Limited and Ms. Dan Yang is deemed to be interested in the 10,611,406 Shares held by I-Bridge under the SFO; and (ii) each of Nova Aqua Limited and Mr. Fu Wei is deemed to be interested in the 10,611,406 Shares held by I-Bridge and the 1,475,000 Shares held by JVC Project I Limited.

(9) As of the Latest Practicable Date, AIHC Master Fund was managed by AIHC Capital Management Limited, which is in turn wholly owned by Zhang Wei. As a result, each of AIH Capital Group Limited and Mr. Zhang Wei is deemed to be interested in the 9,726,094 Shares held by AIHC Master Fund under the SFO.

Save as disclosed above, the Directors are not aware of any person who will, immediately following the completion of the [**REDACTED**] (assuming that the [**REDACTED**] and the [**REDACTED**] are not exercised and all Preferred Shares have been converted into Shares on a one-to-one basis), have any interest and/or short position in the Shares or underlying shares of the Company which will be required to be disclosed to the Company pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meeting of the Company or any other member of the Group.